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Background: HER2 is a well-established prognostic and predictive factor in invasive breast cancer. The role of HER2
in ductal breast carcinoma in situ (DCIS) is debated and recent data have suggested that HER2 is mainly related to
in situ recurrences. Our aim was to study HER2 as a prognostic factor in a large population based cohort of DCIS
with long-term follow-up.
Methods: All 458 patients diagnosed with a primary DCIS 1986–2004 in two Swedish counties were included.
Silver-enhanced in situ hybridisation (SISH) was used for detection of HER2 gene amplification and protein expression
was assessed by immunohistochemistry (IHC) in tissue microarrays. HER2 positivity was defined as amplified HER2 gene
and/or HER2 3+ by IHC. HER2 status in relation to new ipsilateral events (IBE) and Invasive Breast Cancer Recurrences,
local or distant (IBCR) was assessed by Kaplan-Meier survival analyses and Cox proportional hazards regression models.
Results: Primary DCIS was screening-detected in 75.5 % of cases. Breast conserving surgery (BCS) was performed
in 78.6 % of whom 44.0 % received postoperative radiotherapy. No patients received adjuvant endocrine- or
chemotherapy. The majority of DCIS could be HER2 classified (N = 420 (91.7 %)); 132 HER2 positive (31 %) and 288
HER2 negative (69 %)). HER2 positivity was related to large tumor size (P = 0.002), high grade (P < 0.001) and ER- and PR
negativity (P < 0.001 for both). During follow-up (mean 184 months), 106 IBCRs and 105 IBEs were identified among all
458 cases corresponding to 54 in situ and 51 invasive recurrences. Eighteen women died from breast cancer and
another 114 had died from other causes. The risk of IBCR was statistically significantly lower subsequent to a
HER2 positive DCIS compared to a HER2 negative DCIS, (Log-Rank P = 0.03, (HR) 0.60 (95 % CI 0.38–0.94)). Remarkably,
the curves did not separate until after 10 years. In ER-stratified analyses, HER2 positive DCIS was associated with lower
risk of IBCR among women with ER negative DCIS (Log-Rank P = 0.003), but not for women with ER positive DCIS.
Conclusions: Improved prognostic tools for DCIS patients are warranted to tailor adjuvant therapy. Here, we
demonstrate that HER2 positive disease in the primary DCIS is associated with lower risk of recurrent invasive
breast cancer.
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In general, patients with ductal breast carcinoma in situ
(DCIS) have an excellent prognosis in terms of survival
[1, 2]. However, the rate of new ipsilateral events (IBE)
is high, even higher than following invasive breast can-
cer [2]. Almost half of all IBEs subsequent to a DCIS
are invasive cancer and survival after an invasive IBE
has, not surprisingly, been reported to be worse than
after a non-invasive recurrence [3]. The knowledge
about clinical and pathological predictors of recurrence
following DCIS is currently limited [4, 5]. Certain sub-
types of DCIS might be more prone to recur as invasive
cancer and new biological markers may provide add-
itional prognostic and/or treatment predictive value
[6–9]. Recently, genomic-based data from a study using
the Oncotype DX® indicated that it was possible to pre-
dict the local relapse risk for a primary DCIS independ-
ently from classical factors [10].
HER2 is an established negative prognostic factor in
invasive breast cancer [11]. The prognostic significance
of HER2 status in DCIS is, however, less clear [7, 12].
Both the relation of HER2 to risk of recurrence and its
role in the progression from in situ to invasive cancer
have been debated [12]. HER2 over-expression is re-
ported to be more frequent in DCIS than in invasive
cancer [13]. This may seem counterintuitive as HER2 is
proposed to play a role in tumour progression. Some
studies report an even higher proportion of HER2
positivity in micro-invasive cancer [14, 15] and, in pre-
operative tumour biopsies displaying DCIS, HER2 over-
expression has been related to a co-existing invasive
component in the surgical specimen [16, 17]. Further-
more, HER2 is associated with high histopathological
grade both in invasive cancer and in DCIS [18].
HER2 amplification is an important factor in the
classification of molecular subtypes of invasive breast
cancer [19]. An approximation of the gene expres-
sion based subtypes using immunohistochemical
(IHC) detection of HER2, estrogen receptor- (ER)
and progesterone receptor (PR) expression has been
suggested for invasive breast cancer [20]. DCIS has
been divided into the same surrogate molecular sub-
types as invasive breast cancer [6, 21–23] but the prog-
nostic value of these subgroups has not been convincing
in DCIS [8, 24].
We have previously studied the surrogate molecular
subgroups in this population-based DCIS cohort [8, 24].
Those studies indicated a lower risk of invasive recur-
rence in HER2-positive DCIS, although not statistical
significant. We therefore conducted this updated ana-
lysis on the same patient population with further ex-
tended follow-up time and pooled HER2 data focusing
on the role of HER2 status in DCIS and its relation to
prognosis.Methods
Patients
All patients diagnosed with a primary DCIS between
1986 and 2004 in two Swedish counties (Uppland and
Västmanland) were included in this DCIS cohort
(n = 458). The majority underwent breast-conserving
surgery (79 %), and clear surgical margins were ob-
tained in 88 % among all cases irrespective of surgical
intervention. All cases were histopathologically re-
examined. Tumour tissue biopsies of 1.0 mm in dupli-
cate from paraffin blocks of samples taken as part of
standard care were used to construct tissue microarrays
(TMA). Follow up was complete up to December 15th,
2013. This study was approved by the Ethics Commit-
tee at Uppsala University, Sweden (Dnr 2005:118) and
no informed consent was needed.Silver-enhanced In Situ Hybridization (SISH) and IHC
Scoring and IHC protocols are previously described in
detail [21, 25]. SISH was performed on the automated
instrument, Ventana Benchmark (Ventana Medical
Systems, Tucson, AZ), as per the manufacturer’s proto-
cols for the INFORM HER2 DNA probe and chromosome
17 probes. Testing for the HER2 gene and chromosome
17 was performed on sequential sections. Both probes are
labelled with dinitrophenol and denaturation occurred on
the instrument with enzyme digestion in protease 3 for
eight minutes. The detection system used a multimer
labelled with goat anti-rabbit antibody horseradish per-
oxidase as the linking step. Visualization occurred with
the sequential addition of silver acetate as the source of
ionic silver, hydroquinone, and hydrogen peroxide to give
black metallic silver precipitate at the probe site. Coun-
terstaining was performed with hematoxylin II on the
instrument. The time taken for the complete run was
6.5 h. Both HER2 and chromosome 17-detection were
performed on the same slide run. Gene amplification was
assessed using the American Society of Clinical Oncol-
ogy/College of American Pathologists guideline and Aus-
tralian HER2 Advisory Board criteria for single HER2
probe testing (diploid, 1 to 2.5 copies/nucleus; polysemy
>2.5 to 4 copies/nucleus; equivocal, >4 to 6 copies/
nucleus; low-level amplification, >6 to 10 copies/ nu-
cleus; and high-level amplification >10 copies/nucleus)
and for dual HER2/CHR17 probe testing (non-amplified
ratio <1.8; equivocal ratio, 1.8 to 2.2; gene amplification,
>2.2) [26]. The HER2 status was predominantly relying
on the SISH data. For those cases in which SISH failed,
HER2 status was based on the IHC data and cases were
considered HER2 positive if the IHC score was 3+, using
the HercepTest©. As for hormone receptors (estrogen
receptor alpha (ER) and progesterone receptor (PR)),
tumours with 10 % or more nuclei stained were considered
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taken into consideration.Statistic analyses
Baseline characteristics among women with different
HER2 status were compared by Chi-square test for cat-
egorical variables or analysis of variance for continu-
ous variables. Survival analyses were performed using
Kaplan-Meier curves, including the Log-Rank test.
Cox proportional hazards regression models were
used to generate hazard ratios (HRs) with 95 % con-
fidence intervals (CIs), with adjustment for radiother-
apy, age at diagnosis (continuous), tumour size (two
categories: ≤ 25 mm; >25 mm or multifocal), and ER
status. Stratification analyses were performed by
mode of detection, type of surgery and ER in differ-
ent multivariate models. All statistical tests were
two-sided, and p-values less than 0.05 were consid-
ered significant. Data were analysed using the SPSSTable 1 Baseline characteristics by HER2 status in 458 women with
Characteristics All HER2 posit
(n = 458) (n = 132)
n (%) n (%)
Age (years) mean (n = 458) 58.6 57.4
Detection mode (n = 457)
Screening 345 (75.5 %) 108 (81.8 %
Clinically 112 (24.5 %) 24 (18.2 %)
Type of Surgery (n = 457)
BCS 359 (78.6 %) 98 (74.2 %)
Mastectomy 98 (21.4 %) 34 (25.8 %)
Radiotherapy (n = 359)
Yes 158 (44.0 %) 49 (50.0 %)
No 201 (56.0 %) 49 (50.0 %)
Tumor size (mm) (n = 409)
≤ 25 294 (71.9 %) 68 (61.3 %)
> 25 or multifocal 115 (28.1 %) 43 (38.7 %)
Nuclear grade (n = 458)
Grade 1 42 (9.2 %) 1 (0.8 %)
Grade 2 176 (38.4 %) 20 (15.1 %)
Grade 3 240 (52.4 %) 111 (84.1 %
ER status (n = 419)
Positive 307 (73.3 %) 59 (45.7 %)
Negative 112 (26.7 %) 70 (54.3 %)
PR status (n = 409)
Positive 213 (52.1 %) 35 (28.2 %)
Negative 196 (47.93 %) 89 (71.8 %)
BCS breast conserving surgery, RT postoperative radiotherapy
aComparisons between HER2-negative and HER2-positive DCIS were made by χ2-tesStatistics, version 19 (IBM, Chicago, IL, USA) and
SAS 9.3 (Cary, NC, USA).
Primary endpoints were Ipsilateral Breast cancer Events
(IBE) and Invasive Breast Cancer Recurrences (IBCR).
IBEs were divided in new in situ events and invasive IBEs.
As for IBCR, an event was defined as an invasive IBE, a re-
gional recurrence, a contralateral invasive breast cancer or
distant metastasis. IBCR free survival was calculated based
on the time from primary surgery to the date of any inva-
sive breast cancer event, date of death or date of last
follow-up as by December 15th 2013. For an event to be
classified as IBE or IBCR, a minimum of 3 months had to
pass after the primary surgery.
Results
Patient and tumour characteristics
Baseline characteristics by HER2 status are presented in
Table 1. The mean age at diagnosis was 58.6 years, ran-
ging from 30 to 90 years of age. A total of 202 women
were diagnosed in Västerås, whereas the remaining 256a primary DCIS
ive HER2 negative HER2 missing
(n = 288) (n = 38)
n (%) P-valuea n (%)
59.2 0.13 58.8
) 210 (73.2 %) 27 (71.1 %)
77 (26.8 %) 0.05 11 (28.9 %)
233 (81.2 %) 28 (73.7 %)
54 (18.8 %) 0.11 10 (26.3 %)
100 (42.9 %) 9 (32.1 %)
133 (57.1 %) 0.32 19 (67.9 %)
203 (77.2 %) 23 (65.7 %)
60 (22.8 %) 0.002 12 (34.3 %)
34 (11.8 %) 7 (18.4 %)
145 (50.3 %) 11 (28.9 %)
) 109 (37.8 %) <0.001 20 (52.6 %)
243 (86.5 %) 5 (55.6 %)
38 (13.5 %) <0.001 4 (44.4 %)
175 (62.9 %) 4 (57.1 %)
103 (37.1 %) <0.001 3 (42.9 %)
t, except for age and size that was compared by T-test
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DCIS was detected by mammographic screening
(75.5 %). All patients except one underwent surgery with
the majority of patients operated with breast conserving
surgery (BCS) (78.6 %). Surgery was followed by postop-
erative radiotherapy (RT) in 35.2 % of all cases, although
primarily for patients operated with BCS of whom
44.0 % received RT (Table 1). None of the patients re-
ceived hormonal therapy or chemotherapy according to
Swedish clinical guidelines.
Follow-up data
The mean follow up time was 183.5 months (range 3–329
months). A total of 105 IBEs were identified of which
54 were a new in situ and 51 an invasive IBE in theTable 2 Patient- and tumor characteristics of the primary DCIS in re
cancer event (IBE) including risk of in situ IBEs and invasive ipsilatera
(univariate Cox regression analyses)
Characteristics Ipsilateral Breast Events (IBE) in situ IBEs
Among BCS (n = 359) BCS
HR (95 % CI) HR (95 % CI)
Age (years)
< 50 Reference Reference
50–65 0.77 (0.44–1.31) 0.92 (0.41–2.0
> 65 1.19 (0.67–2.12) 1.31 (0.55–3.1
Detection mode
Screening Reference Reference






Yes 0.53 (0.33–0.86) 0.50 (0.25–1.0
Tumor size (mm)
≤ 25 Reference Reference
> 25 / multifocal 1.14 (0.71–1.83) 1.88 (0.97–3.6
Nuclear grade
Grade 1 Reference Reference
Grade 2 0.90 (0.41–1.96) 1.05 (0.30–3.6
Grade 3 0.83 (0.39–1.79) 1.03 (0.30–3.4
ER status
Negative Reference Reference
Positive 0.90 (0.52–1.55) 0.80 (0.38–1.7
PR status
Negative Reference Reference
Positive 0.83 (0.52–1.32) 1.04 (0.53–2.0
RT radiotherapy, BCS breast conserving surgery, IBE ipsilateral breast events, IBCR inentire cohort of 458 patients. Among women treated
with BCS (N = 324), recurrences were detected among
95 women comprising 49 in situ and 46 invasive cases.
Eleven of the in situ IBEs were followed by a subse-
quent invasive IBE. One hundred and six IBCR were
identified. The first invasive event was an invasive IBE
in 50 cases, regional axillary metastasis in four, loco-
regional together with distant metastases or distant
metastasis only in twelve cases and a contralateral inva-
sive cancer in 40 cases. In total, 32 patients developed
generalized disease; fifteen subsequently to an invasive
IBE, eight after an invasive contralateral cancer and
nine had no reported prior local or regional recurrence.
Eighteen women died from breast cancer and another
114 had died from other causes.lation to risk of a breast cancer event. Risk of an ipsilateral breast
l recurrence, respectively, and any invasive recurrence (IBCR)
invasive IBEs Invasive Breast Cancer Recurrence (IBCR)
BCS Among all (n = 458)
HR (95 % CI) HR (95 % CI)
Reference Reference
5) 0.63 (0.30–1.32) 0.68 (0.41–1.12)
1) 1.09 (0.50–2.37) 0.98 (0.57–1.66)
Reference Reference




1) 0.51 (0.27–0.98) 0.91 (0.59–1.41)
Reference Reference
2) 0.64 (0.30–1.34) 0.89 (0.55–1.45)
Reference Reference
3) 0.73 (0.27–1.99) 0.82 (0.38–1.77)
9) 0.63 (0.23–1.69) 0.64 (0.30–1.37)
Reference Reference
1) 1.02 (0.47–2.22) 1.16 (0.70–1.93)
Reference Reference
2) 0.66 (0.35–1.27) 1.06 (0.69–1.63)
vasive breast cancer recurrence
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Of all 458 women, 420 could be HER2 classified using
available SISH or IHC data; 132 were classified as HER2
positive (31.4 %) and 288 as HER2 negative. Of 344 cases
with available SISH data, 118 (34.3 %) were HER2 posi-
tive and of 408 cases with IHC data 103 (25.2 %) were
classified as HER2 positive (i.e. 3+). In comparison, SISH
and IHC data showed concordance in 296 of 332
(89.2 %) cases with available data for both SISH and
IHC. Twenty-nine of those 332 cases were classified as
HER2 2+ by IHC, 21 of those 29 (72.4 %) were SISH
positive and eight (27.6 %) were SISH negative. In 38
cases, data on HER2 status was missing all together.
HER2 status was significantly related to tumor size, nu-
clear grade (NG) and hormone receptor status, and the
HER2 positive tumours tended to be detected by screen-
ing more often than HER2 negative tumors. HER2 status
was not associated with age at diagnosis, type of surgery
or RT (Table 1). In analyses assessing risk of recurrences
according to established patient-and tumor characteristics,Fig. 1 Ipsilateral Breast cancer Events (IBE) according to HER2 status of the
survival analyses (IBE) among women with DCIS treated with breast conser
regarding all ipsilateral events (a), ipsilateral in situ events (b), and ipsilateraclinically detected DCIS were more prone to recur locally
(HR 1.78 (1.04–3.07), larger DCIS lesions were correlated
to a borderline significant increased risk of in situ IBEs
but not invasive IBEs (HR 1.88 (0.97–3.62) and 0.64
(0.30–1.34)), respectively. Other assessed factors were not
associated with recurrences (Table 2).
HER2 and survival analyses
Among the 420 women with available HER2 status, a total
of 102 women experienced recurrences during follow-up.
HER2 positivity in the primary DCIS was not a risk factor
for IBE in women undergoing BCS (Log-Rank P = 0.40,
HR 1.20 (95 % CI, 0.78–1.85)), (Fig. 1a and Table 3). Inter-
estingly, divided by type of IBE, HER2 positivity showed a
borderline statistically significant increased risk of in situ
IBEs (Log-Rank P = 0.09, HR 1.63 (95 % CI, 0.92–2.89),
and no association with risk of invasive IBEs (Log-Rank
p = 0.48, HR 0.78 (95 % CI, 0.40–1.55)), (Fig. 1b–c and
Table 3). Results from the multivariate analyses did not
differ substantially from the univariate analyses (Table 3).primary DCIS. Kaplan-Meier plots showing ipsilateral recurrence-free
ving surgery (BCS) with respect to HER2 status of the primary DCIS
l invasive events (c)
Table 3 Cox regression analyses by HER2 status in 458 women




HR (95 % CI) HR (95 % CI)
Ipsilateral Breast Events (IBE)
BCS (n = 331) (events = 95)
Univariate HR (95 % CI) 1.20 (0.78–1.85) (Ref)
aAdjusted HR (95 % CI) 1.27 (0.83–1.96) (Ref)
bAdjusted HR (95 % CI) 1.17 (0.75–1.83) (Ref)
cAdjusted HR (95 % CI) 1.22 (0.76–1.95) (Ref)
BCS, in situ IBEs (events = 49)
Univariate HR (95 % CI) 1.63 (0.92–2.89) (Ref)
aAdjusted HR (95 % CI) 1.76 (0.99–3.11) (Ref)
bAdjusted HR (95 % CI) 1.40 (0.77–2.54) (Ref)
cAdjusted HR (95 % CI) 1.65 (0.88–3.11) (Ref)
BCS, invasive IBEs (events = 46)
Univariate HR (95 % CI) 0.78 (0.40–1.55) (Ref)
aAdjusted HR (95 % CI) 0.83 (0.42–1.64) (Ref)
bAdjusted HR (95 % CI) 0.87 (0.43–1.75) (Ref)
cAdjusted HR (95 % CI) 0.80 (0.38–1.66) (Ref)
Invasive Breast Cancer Recurrence
(IBCR)
All patients (n = 420) (Events = 102)
Univariate HR (95 % CI) 0.60 (0.38–0.94) (Ref)
aAdjusted HR (95 % CI) 0.58 (0.38–0.95) (Ref)
bAdjusted HR (95 % CI) 0.59 (0.37–0.95) (Ref)
cAdjusted HR (95 % CI) 0.59 (0.36–0.98) (Ref)
BCS breast conserving surgery
aAdjusted for radiotherapy
bAdjusted for radiotherapy, age at diagnosis (continuous) and size
cAdjusted for radiotherapy, age at diagnosis and ER
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subsequent to a HER2 positive DCIS compared to a HER2
negative primary DCIS (Log-Rank P = 0.03, HR 0.60 (95 %
CI, 0.38–0.94)) (Fig. 2 and Table 3). Remarkably, the
curves in the Kaplan-Meier plot did not separate until
after almost 10 years (Fig. 2). In the multivariate analyses,
HRs after adjustments were very similar to the crude
analyses (Table 3).
The survival analyses were stratified for ER-status, and
for patients with an ER negative DCIS, HER2 positivity
predicted a significantly lower risk of IBCR (Log-Rank,
P = 0.003), (Fig. 3a), which was not the case for ER posi-
tive DCIS patients (Log-Rank, P = 0.76), (Fig. 3b). In
analyses restricted to women who undergoing BCS, ER
status remained an effect modifier for the association be-
tween HER2 status and IBCR.
The prognostic value of age was studied in survival ana-
lysis using age as at dichotomous variable of ≤ 50 years
(N = 141, 31 %) or > 50 years (N = 317, 69 %). Age was not
proven to be a prognostic indicator of neither invasive nor
in situ recurrence (data not shown). However, age added
substantial information to the prognostic value of HER2
status. For presumably premenopausal women aged 50 or
below, HER2 expression in the DCIS revealed no prognos-
tic information (Fig. 3c). In contrast, for women who were
older than 50 years of age at diagnosis, HER2 positivity
was associated with a markedly improved recurrence-free
survival for invasive disease (Log-Rank, P = 0.002), (Fig. 3d).
The age-stratified analyses for in situ IBEs did not reveal
any significant results.
Discussion
In this long-term follow-up DCIS cohort, positive HER2
status in the primary lesion predicted lower risk of late
invasive breast cancer recurrence compared to negative
HER2 status in the primary DCIS. HER2 positivity did
on the other hand indicate a non-significant higher risk
of local in situ IBEs.
DCIS is by definition a non-invasive disease exerting a
rather high risk of local recurrence but an especially low
risk of lethal outcome from the disease [27]. However,
an increasing rate of early-stage disease, including DCIS,
is observed due to mammography screening [28]. The
ideal screening method aims at fractioning indolent
disease from cancers that will ultimately cause harm if
undetected at an early stage. Current mammography
methods are incapable of characterising the aggressiveness
of a given breast tumor, and tissue based assessment of
biological entities is warranted for improved clinical
decision-making [1, 29, 30]. DCIS includes a plethora of
diseases ranging from conditions where active surveillance
might be adequate, to conditions where tumors should be
surgically removed followed by adjuvant treatment. Pre-
diction of recurrences is thus a high priority; bothprognostic and treatment predictive factors should be
identified [29].
Previous studies have shown increased risk of DCIS
recurrences among patients with HER2 positive disease
in the primary DCIS [31, 32]. These findings were
vaguely indicated but not statistically significantly con-
firmed in this study. More importantly, HER2 status was
predictive of invasive recurrences in this study showing
that HER2 positive tumors were less reluctant to recur
as an invasive tumor. The positive prognostic value of
HER2 in DCIS demonstrated here might seem counter-
intuitive given the data showing HER2 to be positively
related to tumor size, multifocality and nuclear grade and
may reflect an independent role of HER2 in DCIS as a
long-term prognostic biomarker. This study includes an
extensive long-term follow-up, which enabled the detec-
tion of the lower incidence of late-recurrences among
Fig. 2 Invasive recurrence-free-survival according to HER2 status of the primary DCIS. Kaplan-Meier plot showing invasive recurrence-free survival
analyses (IBCR) among women with a DCIS with respect to HER2 status of the primary DCIS
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curves for invasive recurrences were concordant for
several years, and not until 10 years after the primary
DCIS, did the curves separate. The discordances between
our results and the results generated by Kerlikowske et al.
[32] may well be explained by the differences in follow-up
time. More importantly, the endpoints applied in this
study are not identical to previous studies among which
any ipsilateral recurrence regardless of type has served as
endpoint. Our results stating that HER2 positive DCIS is a
beneficial prognostic marker for invasive recurrent disease
highlights the need for studying several different end-
points to understand the prognostic value of a given bio-
logical marker. Presumably the key endpoint should be
invasive recurrence representing the actual threat to the
patient’s life as discussed in the review by Benson et al.
stating the main goals of DCIS treatment to be prevention
of recurrent invasive disease, minimised treatment-related
morbidity, and optimised cosmetics [29].
In a previous publication, we evaluated the prognostic
impact of molecular subtypes defined by the immunohis-
tochemical surrogate classification [24]. The subtypes were
based on the proposed classification for invasive breast
cancer according to the St Gallen consensus meeting in
2011 [20]. HER2 cases were thus presented in two sub-
types, i.e. Luminal B(HER2+) and HER2 + (ER-/PR-) leav-
ing few cases in each subtype, which might explain the
non-significant data generated in that study. Herein, we
report significant results for HER2 as a prognostic
marker for recurrent invasive disease, presumable proneto the facts that, in this study, all HER2 positive DCIS
were analysed together and moreover, the follow-up
period has been extended.
The significantly reduced risk estimates for patients
with HER2 positive DCIS might help identifying a low-
risk group for whom adjuvant treatment after surgical
excision could safely be omitted. To keep overtreatment
to an innocuous minimum is essential for DCIS-patients
among whom a substantial amount of the lesions may
be of limited clinical importance [28].
This study has several strengths, such as its relatively
large sample size and confirmation of all events by a
physician. Another important strength was the long-
term follow-up of more than 15 years (mean). During
follow-up invasive recurrences were identified in 23 %
(106/458) of the women with a previous DCIS. From a
biological point of view, the identified regional or distant
metastases have most likely evolved from an invasive
foci in the breast, which could have occurred at any time
between the DCIS diagnosis and the diagnosis of meta-
static disease, although not detected and therefore not
possible to report in this study. The number of invasive
recurrences does, however, correspond with numbers
from previous publications on DCIS patients showing a
recurrence rate of 25 % within 10 years of follow-up,
50 % of these being invasive recurrences [33], and 18 %
during 5 years of follow-up [34]. Unequal recurrence-
estimates may be explained be differences in follow-up
length and the fact that no systemic endocrine treatment
is recommended Swedish DCIS patients.
Fig. 3 Invasive recurrence-free-survival according to HER2 of the primary DCIS, stratified for ER status and age, respectively. Kaplan-Meier analyses
stratified for ER status of the primary DCIS, demonstrating invasive recurrence-free survival (IBCR) with respect to HER2 status of the primary DCIS
among ER negative (a) and ER positive DCIS patients (b). Additional Kaplan-Meier curves show analyses stratified for age at diagnosis
(≤50 years/> 50 years) displaying invasive recurrence-free survival (IBCR) according to HER2 status of the primary DCIS among young patients
(≤50 years at diagnosis), (c) and older patients with age 50 years or above at diagnosis (d)
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terpretation of our results. All evaluated tumor bio-
markers were investigated on TMAs, which may have
limited the assessment of heterogeneous expression
compared to whole sections. Previous validation studies
of TMA-based biomarker assessment, however, show ac-
curate concordance between TMAs and whole sections
motivating use of TMAs for routine breast biomarker (ER,
PR, HER2) analyses in the clinical setting [35]. A previous
publication including a subset of this study population,
showed an overall concordance of 80 % between TMAs
and whole sections for IHC assessment of ER, PR, and
HER2, and notably the prognostic value of these markers
was similar irrespective of assessment based on TMA or
whole sections [36]. This study is predominantly based on
SISH regarding HER2 status with an anticipated high ac-
curacy compared to IHC [37]. Breast conserving surgery
represents the surgical intervention predominantly used in
our cohort. Compared to mastectomy, the outcome fol-
lowing this surgical approach requires higher accuracy inpre-surgical imaging of the tumor extend. No data on pre-
surgical imaging was however available for this study and
differences could not be addressed further, The challenge
of surgical margins differ depending of surgical method as
evidenced in this cohort with clear margins obtained in
94 % of cases undergoing mastectomy compared to 86 %
among the women who underwent breast conserving sur-
gery. However, no association between surgical method
and HER2 status was found, and the risk of confounding
by surgical method is considered small.
HER2 positive disease is a strong predictor for impaired
recurrence-free survival in invasive breast cancer, oppos-
ing the results on DCIS in this study. This controversy
may reflect the diverse expression of HER2 in invasive
lesions and adjacent DCIS components as recently dis-
cussed in a review by Cowell et al. [30]. The tentative
explanations given are that HER2 amplification may either
have been lost in the progression from ductal carcinoma
in situ to invasive breast cancer, or that the invasive
component has arisen from a DCIS clone without HER2
Borgquist et al. BMC Cancer  (2015) 15:468 Page 9 of 10amplification [30]. Biologically, the striking issue is why
progression to invasive disease would imply loss of HER2
amplification, which warrants further attention.
Although this study implies, that patients with HER2
positive DCIS are less likely to experience recurrent
invasive disease, the HER2 positive DCIS disease has
substantial clinical interest as a targetable early-stage
disease. This has been acknowledged by recently
conducted clinical trials testing the efficacy of HER2
targeting therapy with lapatinib in DCIS patients
(ClinicalTrials.gov NCT00555152 and NCT00857714,
respectively). The results of these trials are currently
not published, however the trial results by Estevés et al.
assessing lapatinib in the pre-surgical setting reported
significant inhibition of HER2 signalling and reduced
tumor size following 4 weeks of treatment in HER2
positive DCIS patients [38]. Further, other biomarker
trials have assessed the effects of trastuzumab in DCIS
patients, among which, one trial has reported the
results, showing no significant tumor effects in terms
of proliferation and apoptosis after a single-dose mono-
therapy trastuzumab pre-surgically [39]. None of these
studies have addressed the long-term benefits of HER2
targeted therapy in DCIS. However, a currently recruit-
ing phase III randomized trial prescribing trastuzumab
versus placebo concomitantly with radiotherapy, may
shed light over the long-term effects (ClinicalTrials
NCT00769379).Conclusions
Clinical decision making for DCIS patients is still chal-
lenged by the inability to predict recurrence or, most
importantly, progression to invasive disease. In line with
the models developed for invasive breast cancer, such as
Adjuvant! [40], a comprehensive set of solid biomarkers
for DCIS prognosis and treatment prediction has repeat-
edly been requested. In this large DCIS cohort with exten-
sive follow-up, we demonstrate significantly improved
long-term invasive disease-free survival for patients with
HER2 positive disease in the primary DCIS. These results
indicate that HER2 status could add significant informa-
tion in future development of prognostic and predictive
DCIS models.
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